VJHemOnc is committed to improving our service to you

IMW 2019 | Clonal Hematopoeisis of undetermined potential

VJHemOnc is committed to improving our service to you

Tarek H Mouhieddine

Tarek H Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, discusses how multiple myeloma patients with clonal hematopoeisis of undetermined potential (CHIP) are at an increased risk of cardiovascular disease and additional hematological malignancies. Dr Mouhieddine goes on to explain how immunomodulatory maintenance negates the negative effects of CHIP. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter